Nextwave Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXTWAVE
NEXTWAVE has two approved drugs.
There are sixteen US patents protecting NEXTWAVE drugs.
Drugs and US Patents for Nextwave
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | 9,545,399 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | 11,103,494 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | 8,202,537 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for NEXTWAVE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Oral Suspension | 5 mg/mL | ➤ Subscribe | 2013-08-02 |
International Patents for Nextwave Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200812649 | ⤷ Start Trial |
| Spain | 2721900 | ⤷ Start Trial |
| Spain | 2396039 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

